346673-06-1
346673-06-1 structure
- Name: CAY10598
- Chemical Name: 5-(3-hydroxy-4-phenylbut-1-enyl)-1-[6-(2H-tetrazol-5-yl)hexyl]pyrrolidin-2-one
- CAS Number: 346673-06-1
- Molecular Formula: C21H29N5O2
- Molecular Weight: 383.487
- Catalog: Signaling Pathways GPCR/G Protein Prostaglandin Receptor
- Create Date: 2016-05-06 13:50:51
- Modify Date: 2024-01-08 19:04:52
-
TCS 2510 is a selective EP4 agonist. TCS 2510 can be used for the research of metabolic diseases[1].
| Name | 5-(3-hydroxy-4-phenylbut-1-enyl)-1-[6-(2H-tetrazol-5-yl)hexyl]pyrrolidin-2-one |
|---|---|
| Synonyms |
2-Pyrrolidinone, 5-[(1E,3S)-3-hydroxy-4-phenyl-1-buten-1-yl]-1-[6-(2H-tetrazol-5-yl)hexyl]-, (5R)-
(5R)-5-[(1E,3S)-3-Hydroxy-4-phenyl-1-buten-1-yl]-1-[6-(2H-tetrazol-5-yl)hexyl]-2-pyrrolidinone |
| Description | TCS 2510 is a selective EP4 agonist. TCS 2510 can be used for the research of metabolic diseases[1]. |
|---|---|
| Related Catalog | |
| Target |
EP4 |
| In Vitro | TCS 2510 (0.001~100 μM; GLUTag cells) stimulates glucagon like peptide 1 secretion. TCS2510 activates the Gas signaling pathway. TCS 2510 (10 μM; 2~24 h; GLUTag cells) increases the Gcg mRNA expression levels. TCS 2510 produces a concentration dependent increase in cAMP levels in GLUTag cells with EC50 of 20 nM and the maximal stimulation of 60 % over the basal cAMP levels. The decrease in cell impedance in GLUTag cells observed with TCS 2510 is concentration dependent with IC50 of 15 nM. TCS 2510 produces a concentration-dependent increase in glucagon like peptide 2 secretion in GLUTag cells[1]. |
| In Vivo | TCS 2510 (0.1~10 mg/kg; p.o.) produces a dose-dependent elevation in plasma glucagon like peptide 1 levels in fasted mice measured 15 min after compound administration[1]. TCS 2510 (10 mg/kg; p.o.) increases plasma glucagon like peptide 1 levels up to 8-fold over the basal hormone levels[1]. TCS 2510 (1~10 mg/kg; p.o) affords a significant elevation in plasma glucagon like peptide 2 levels[1] Animal Model: Mice[1] Dosage: 0.1~10 mg/kg Administration: P.o. Result: Produced a dose-dependent elevation in plasma glucagon like peptide 1 levels in fasted mice measured 15 min after compound administration. Animal Model: Mice[1] Dosage: 10 mg/kg Administration: P.o. Result: Increased plasma glucagon like peptide 1 levels up to 8-fold over the basal hormone levels. Animal Model: Mice[1] Dosage: 1~10 mg/kg Administration: P.o. Result: Afforded a significant elevation in plasma glucagon like peptide 2 levels. |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 632.0±65.0 °C at 760 mmHg |
| Molecular Formula | C21H29N5O2 |
| Molecular Weight | 383.487 |
| Flash Point | 336.0±34.3 °C |
| Exact Mass | 383.232117 |
| PSA | 95.00000 |
| LogP | 1.51 |
| Vapour Pressure | 0.0±1.9 mmHg at 25°C |
| Index of Refraction | 1.626 |